Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis

Eur J Clin Pharmacol. 1987;33(5):469-72. doi: 10.1007/BF00544237.

Abstract

Plasma and ascitic fluid concentrations of pefloxacin in 10 cirrhotic patients and 8 healthy volunteers were determined following administration of a single oral dose of 400 mg. The mean elimination half-life was significantly increased in the patients (29.0 h) compared to in 8 healthy volunteers (12.3 h). In patients, the total plasma clearance (2.71 vs 6.85 l/h) and volume of distribution (1.12 vs 1.67 l/kg) were decreased. Estimated by the ratio of the AUC in peritoneal fluid and plasma, ascitic fluid penetration was 68% after one oral dose, and pronounced accumulation of pefloxacin in ascites was found after repeated doses. Oral pefloxacin would seem to be a convenient and useful treatment of spontaneous, gram-negative, bacterial peritonitis in cirrhosis. However, the decreased hepatic metabolism of the drug leads to a marked accumulation in plasma and ascites after repeated doses, and a reduced dose is required in these patients.

MeSH terms

  • Adult
  • Aged
  • Anti-Infective Agents / blood
  • Anti-Infective Agents / pharmacokinetics*
  • Ascitic Fluid / metabolism*
  • Diffusion
  • Female
  • Humans
  • Liver Cirrhosis, Alcoholic / metabolism*
  • Male
  • Middle Aged
  • Norfloxacin / analogs & derivatives*
  • Norfloxacin / blood
  • Norfloxacin / pharmacokinetics
  • Pefloxacin

Substances

  • Anti-Infective Agents
  • Pefloxacin
  • Norfloxacin